nanoform the
stars that will
shine the brightest nanoform
the stars
that will
shine the brightest

The STARMAP^® AI platform predicts the performance of your molecule in Nanoform’s technology

• The STARMAP^® model is an AI-enabled digital twin of Nanoform’s manufacturing platform
• By predicting performance and outcomes using the platform, Nanoform can focus on your most promising molecules.

Nanoform have developed the STARMAP^® platform, an advanced AI algorithm capable of predicting the ‘nanoformability’ of drug molecules. The platform uses cutting-edge sparse-data AI to accurately assess an API’s solubility in supercritical carbon dioxide and propensity to crystallize, enabling scientists to conduct in silico experiments on single chemical entities or vast libraries of candidate molecules.

Access to the STARMAP^® AI platform is available via a secure, subscription-based online portal, allowing partners to run virtual Nanoforming experiments from their own desktop while ensuring complete data confidentiality and encryption. Nanoform recently granted AstraZeneca a global license to the STARMAP^® platform, to integrate Nanoform’s technology into their own drug discovery and lifecycle management workflows. This partnership underscores the growing recognition of the STARMAP^® suite’s potential to transform drug development. It ensures that AstraZeneca are able to use our technology to target those in-house candidates with the greatest chance of success, and provides them with a cost-efficient approach to drug development.

Using the platform, Nanoform’s partners are able to select drug candidates that are not suitable for traditional bioavailability enhancement approaches, and extends the toolkit of solutions available for their develpment pipelines.